Sermorelin
Refilling Soon
This peptide is currently out of stock. Get notified the moment it's available.
About Sermorelin
Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino acid peptide representing the biologically active N-terminal fragment of endogenous Growth Hormone Releasing Hormone. As the shortest GHRH fragment retaining full receptor binding activity, Sermorelin was among the first GHRH analogues to receive FDA approval (1997) for paediatric GH deficiency, establishing it as one of the most historically validated GHRH research tools. Its mechanism is selective agonism at the GHRH receptor on pituitary somatotrophs, stimulating the synthesis and pulsatile secretion of endogenous GH without bypassing the pituitary's natural negative feedback mechanisms. This pituitary-dependent action distinguishes Sermorelin from exogenous rhGH and makes it a preferred tool for studying the intact GH axis with preserved feedback control. Research applications include GH-deficiency models, age-related somatopause research, body composition studies, sleep quality research (GH plays a critical role in slow-wave sleep architecture), and comparative pharmacology against longer-acting GHRH analogues such as Tesamorelin and CJC-1295. Supplied at ≥99% HPLC purity.
Usage Guidelines
✓ Suitable For
- Ideal for intact GH axis research with preserved pituitary negative feedback
- Well suited for somatopause age-related GH decline and body composition studies
- Sleep quality and GH pulse architecture research benefit from Sermorelin's physiological mechanism
- Excellent reference compound for comparative GHRH analogue pharmacology studies
✗ Not Recommended For
- Not for use without endocrinological guidance — GH axis modulation requires expert oversight
- Not suitable for individuals with known pituitary tumours or hypothalamic conditions
- Not intended for human therapeutic use outside of approved clinical research settings
- Consult an endocrinologist or research physician before initiating any GH axis protocol